Fits and Starts: Trial Results from the CTAD Conference
In Barcelona, data ran the gamut from a few hopeful little hints on new treatments to mixed signals on familiar players, and failed drugs thrown on the scrap heap.
ALL NEWS
5752 RESULTS
Sort By:
- Most Recent
- Most Commented
A New Link Between Pesticides and Parkinson's Disease
Parkinson's disease is one of the most common neurodegenerative diseases, affecting about one percent of all people over the age of 65. It is characterized by rigidity, bradykinesia and tremors, which are caused by the progressive degeneration of dopamine-containing neurons...
Positive Phase 2 Results Claimed for Masitinib in Alzheimer’s
Topline results suggested that the anti-inflammatory treatment stabilized cognition and function over six months. The trial did not include biomarkers.
GWAS Fingers Tau and Other Genes for Parkinsonian Tauopathy
Progressive supranuclear palsy is a poorly understood movement disorder that has come to be of intense interest to age-related neurodegenerative disease researchers...
Taiwan FDA Approves MagQu Plasma Aβ And Tau Tests
Assays will help doctors diagnose Alzheimer’s disease and amnestic mild cognitive impairment in Taiwanese clinics.
In the Running: Trial Results from CTAD Conference
Besides the big-gun antibodies and BACE inhibitors, smaller, lesser-known drug programs are inching their way through the clinical trials pipeline. As is often the case, Phase 1 seems encouraging.
Sharp Centenarians Shrug Off Effects of Alzheimer’s Pathology
Despite plaques and tangles in the brain, this group, on average, maintains their cognitive skills over two to four years, suggesting the presence of resilience factors.
Are the Long Aβ Peptides the Real Bad Guys?
Among 14 familial Alzheimer’s APP mutations, two don’t change the Aβ42/Aβ40 ratio, but all of them yield long peptides of 45 to 49 residues that hide out in the membrane.
Doubling Down on Sequencing Serves up More Alzheimer’s Genes
New genetic variants emerged by harmonizing whole-exome-sequencing data across continents, and by using imputation to plumb the depths of existing GWAS. One variant encodes a microglial phospholipid transporter.
ALZgerm Challenge–No Winner, But Small Prizes to 8 Scientists
Researchers split $200,000 for their theories on the role of six microbes—one virus, four bacteria, and one parasite—in Alzheimer’s.
Task Force Focuses on Tracing Brain Amyloid
Online training for use of Amyvid, the first FDA-approved Aβ imaging ligand, is now up and running,even as a task force convened by the Society of Nuclear Medicine and the Alzheimer's Association scrambles to formulate some expert guidelines on how ...
DIAN: International Network to Chart AD Preclinical Decade
The rarest kind of Alzheimer's disease, the form that is inherited from parent to child with a cruel 50 percent likelihood, has long been marked by its untapped opportunities. Affected families have made possible both the discovery of the first three ...
The Alzheimer's Disease Neuroimaging Initiative
The Alzheimer's Disease Neuroimaging Initiative is the most expensive AD study the NIH has ever funded. Expectations are that it will speak with the authoritative voice of a 58-center, three-year observation of 819 research participants above a ...
More Needed Than Ever, Brain Banks Are Modernizing But Face Funding Crunch
Banked brain tissue enables crucial advances in the understanding and treatment of degenerative disorders. As appreciation of the many different variants of neurodegenerative disease is growing, well-preserved tissue is in more demand than ever. Are the ...
The Mega-Appeal of Nanomedicine
The European Union is banking on big returns from nanotechnology in the fight against AD. European Union Throws Megabucks at Nanomedicine EU Consortium Applies Nanotechnology to Study AD ...
Current Filters
- Date Range : All x